ImmunoCellular cut in half as ICT-107 misses primary OS endpoint
Dec. 11, 2013 4:23 PM ETEOM Pharmaceuticals Holdings, Inc. (IMUC)IMUCBy: Colin Lokey, SA News Editor6 Comments
- ImmunoCellular (OTCPK:IMUC) collapses 50% AH.
- The company is out with results from a Phase 2 study of ICT-107 in newly diagnosed glioblastoma multiforme.
- ICT-107 showed statistically significant PFS superiority over placebo. K-M curves (entire sample of 124 patients): Favors ICT-107; HR of 0.56; p=0.014; median PFS increase was two months. K-M curves (per-protocol population): Favors ICT-107; HR of 0.53; p=0.0074; median PFS increase was three months.
- OS K-M curves fail to hit statistical significance. OS was the primary endpoint. Summary (intent-to-treat): HR of 0.87; p=0.58. Summary (per-protocol): HR of 0.79; p=0.40.
- For more, see here.